Logo
Logo

About Apalutamide (Amorphous & Form B) API

Product
  • Therapeutic CategoryAnti-Cancer/ Oncology

  • CAS Number

    956104-40-8

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    Brazil DMF, USDMF

Mechanism of Action

Apalutamide is an Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription. A major metabolite, N-desmethyl apalutamide, is a less potent inhibitor of AR, and exhibited one-third the activity of apalutamide in an in vitro transcriptional reporter assay. Apalutamide administration caused decreased tumor cell proliferation and increased apoptosis leading to decreased tumor volume in mouse xenograft models of prostate cancer.

Indication

ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Related APIs

Abiraterone Acetate

Anti-Cancer/ Oncology

arrow

Adagrasib

Anti-Cancer/ Oncology

arrow

Apalutamide (Amorphous & Form B)

Anti-Cancer/ Oncology

arrow

Azacitidine

Anti-Cancer/ Oncology

arrow

Bendamustine Hydrochloride

Anti-Cancer/ Oncology

arrow

Bortezomib

Anti-Cancer/ Oncology

arrow

Cabazitaxel

Anti-Cancer/ Oncology

arrow

Cabozantinib S-Malate

Anti-Cancer/ Oncology

arrow

Capecitabine

Anti-Cancer/ Oncology

arrow

Carfilzomib

Anti-Cancer/ Oncology

arrow

Darolutamide

Anti-Cancer/ Oncology

arrow

Dasatinib (Monohydrate)

Anti-Cancer/ Oncology

arrow

Decitabine

Anti-Cancer/ Oncology

arrow

Deucravacitinib

Anti-Cancer/ Oncology

arrow

Fruquintinib

Anti-Cancer/ Oncology

arrow

Gemcitabine Hydrochloride

Anti-Cancer/ Oncology

arrow

Granisteron

Anti-Cancer/ Oncology

arrow

Lenalidomide (Form A)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate ( MIBK Solvate)

Anti-Cancer/ Oncology

arrow

Lomustine

Anti-Cancer/ Oncology

arrow

Midostaurin

Anti-Cancer/ Oncology

arrow

Nilotinib Hydrochloride Monohydrate (Form B)

Anti-Cancer/ Oncology

arrow

Olaparib (Form A)

Anti-Cancer/ Oncology

arrow

Palbociclib

Anti-Cancer/ Oncology

arrow

Pazopanib

Anti-Cancer/ Oncology

arrow

Pemetrexed Disodium Heptahydrate

Anti-Cancer/ Oncology

arrow

Pirtobrutinib

Anti-Cancer/ Oncology

arrow

Pomalidomide

Anti-Cancer/ Oncology

arrow

Relugolix

Anti-Cancer/ Oncology

arrow

Ripretinib

Anti-Cancer/ Oncology

arrow

Tucatinib

Anti-Cancer/ Oncology

arrow

Venetoclax

Anti-Cancer/ Oncology

arrow

Zanubrutinib

Anti-Cancer/ Oncology

arrow

Zoledronic Acid

Anti-Cancer/ Oncology

arrow

Cabozantinib Hydrochloride

Anti-Cancer/ Oncology

arrow

Eribulin Mesylate

Anti-Cancer/ Oncology

arrow

Enzalutamide (Crystalline & Premix)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate (Form-C)

Anti-Cancer/ Oncology

arrow

Niraparib Tosylate

Anti-Cancer/ Oncology

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Description not provided

FAQs

What are the steps in monitoring and testing while taking Apalutamide?
  • This medicine may cause dizziness, tiredness, seizures, and an increase risk for falls and fractures. Do not drive or do anything else that could be dangerous until you know how this medicine affects you. If you plan to have children, talk with your doctor before using this medicine.

How do you store Apalutamide API ?
  • Amorphous form is stable for 3 months at room temperature and recommended storage conditions of 2-8°C. Extended stability will be established.

What is the polymorph form available for Apalutamide API?
  • We offer Crystalline Form-B

What is the dosage form available for Apalutamide ?
  • Available in Tablet dosage form with strength of 60 Mg

What are the DMFs available for Apalutamide API ?
  • Dr.Reddys is the early mover in Apalutamide API manufacturing and files the USDMF

What is the BCS classification for Apalutamide API?
  • Apalutamide belongs to class 2 of BCS classification.


     

What is primary purpose of using the Apalutamide API?
  • Apalutamide is an androgen receptor inhibitor used to treat non metastatic, castration resistant prostate cancer.


     

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.